MedTrace Logo

A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers

NCT07162441 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-09-09

No results posted yet for this study

Summary

This study is open-label, multiple-dose, two-intervention group, single-sequence, crossover design to compare the safety and pharmacokinetics of UIC202502 and UIC202505 when administered alone or in combination.

Conditions

Interventions

DRUG

treatment A

UIC202502 1 Tab/day for 7 days

DRUG

treatment B

UIC202505 1 Tab/day for 7 days

DRUG

treatment C

UIC202502+UIC202505 2 Tab/day for 7 days

Sponsors & Collaborators

  • Korea United Pharm. Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-12
Primary Completion
2025-09-30
Completion
2026-03-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07162441 on ClinicalTrials.gov